Department of Otolaryngology, Harvard Medical School, Boston, Massachusetts.
Department of Otolaryngology, University of Michigan Medical School, Ann Arbor.
JAMA Otolaryngol Head Neck Surg. 2016 Jul 1;142(7):627-33. doi: 10.1001/jamaoto.2016.0937.
Antireflux medication has been endorsed as a useful adjunctive therapy for chronic rhinosinusitis, but its use remains controversial.
To determine whether chronic rhinosinusitis is associated with administration of proton pump inhibitors, histamine2-receptor antagonists, antacids, or prokinetic agents; whether practice patterns vary according to visit setting; and whether those patterns vary according to the presence or absence of potentially confounding conditions.
DESIGN, SETTING, AND PARTICIPANTS: A cross-sectional analysis was performed of data from January 1, 2005, to December 31, 2010, from the National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey, which included 590 772 observations representing 7 191 711 480 ambulatory care visits. Univariate, multivariate, and stratified analyses were performed from January 1, 2005, to December 31, 2010.
Chronic rhinosinusitis.
The probability of receiving antireflux medications was the main measured outcome.
Of 7 191 711 480 ambulatory care visits, those for chronic rhinosinusitis were not more likely to result in the administration of proton pump inhibitors (odds ratio, 1.00; 95% CI, 0.62-1.63; P = .99) or antacids and prokinetic agents (odds ratio, 1.24; 95% CI, 0.30-5.10; P = .77). In addition, patients with chronic rhinosinusitis were less likely to receive histamine2-receptor antagonists than were those without chronic rhinosinusitis, even when adjusted for age, sex, race/ethnicity, visit setting, other antireflux agents, and presence or absence of gastroesophageal reflux, laryngopharyngeal reflux, or allergy diagnoses (odds ratio, 0.25; 95% CI, 0.12-0.57; P = .001).
National practice patterns observed thus far have not favored the use of proton pump inhibitors, histamine2-receptor antagonists, antacids, or prokinetic agents for chronic rhinosinusitis.
抗反流药物已被认可为慢性鼻-鼻窦炎的一种有用的辅助治疗方法,但它的使用仍存在争议。
确定慢性鼻-鼻窦炎是否与质子泵抑制剂、组胺 2 受体拮抗剂、抗酸剂或促动力剂的使用有关;就诊环境是否会影响治疗模式;以及这些模式是否会因潜在混杂条件的存在或缺失而有所不同。
设计、地点和参与者:对 2005 年 1 月 1 日至 2010 年 12 月 31 日期间来自国家门诊医疗调查和国家医院门诊医疗调查的数据进行了横断面分析,这些数据共包括 590772 次就诊,代表了 7191711480 次门诊就诊。从 2005 年 1 月 1 日至 2010 年 12 月 31 日,进行了单变量、多变量和分层分析。
慢性鼻-鼻窦炎。
接受抗反流药物的概率是主要的测量结果。
在 7191711480 次门诊就诊中,慢性鼻-鼻窦炎就诊者接受质子泵抑制剂治疗的可能性并不更高(比值比,1.00;95%置信区间,0.62-1.63;P=0.99)或抗酸剂和促动力剂(比值比,1.24;95%置信区间,0.30-5.10;P=0.77)。此外,与没有慢性鼻-鼻窦炎的患者相比,患有慢性鼻-鼻窦炎的患者接受组胺 2 受体拮抗剂的可能性更小,即使调整了年龄、性别、种族/民族、就诊环境、其他抗反流药物以及胃食管反流、喉咽反流或过敏诊断的存在与否(比值比,0.25;95%置信区间,0.12-0.57;P=0.001)。
迄今为止观察到的全国治疗模式并未倾向于使用质子泵抑制剂、组胺 2 受体拮抗剂、抗酸剂或促动力剂治疗慢性鼻-鼻窦炎。